Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 1 984.5 JPY -0.13%
Market Cap: 2.2T JPY

Olympus Corp
Other Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Olympus Corp
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Olympus Corp
TSE:7733
Other Equity
ÂĄ152.8B
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
25%
Terumo Corp
TSE:4543
Other Equity
ÂĄ287.9B
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
13%
Sysmex Corp
TSE:6869
Other Equity
ÂĄ48.6B
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
17%
Nihon Kohden Corp
TSE:6849
Other Equity
ÂĄ6.3B
CAGR 3-Years
5%
CAGR 5-Years
100%
CAGR 10-Years
6%
JEOL Ltd
TSE:6951
Other Equity
ÂĄ4.2B
CAGR 3-Years
42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fukuda Denshi Co Ltd
TSE:6960
Other Equity
ÂĄ1.6B
CAGR 3-Years
99%
CAGR 5-Years
N/A
CAGR 10-Years
15%
No Stocks Found

Olympus Corp
Glance View

Market Cap
2.2T JPY
Industry
Health Care

Olympus Corporation, originating from the heart of Japan in 1919, has evolved into a global powerhouse, particularly revered for its contributions to the field of optics and imaging. Initially carving its reputation through crafting precision microscope lenses, Olympus seamlessly expanded its capabilities into the realms of endoscopy and digital imaging. This strategic pivot not only defined its legacy but firmly anchored its presence in the medical world, where it became a leader in endoscopic technology. The company adeptly leveraged its expertise to revolutionize medical diagnostics and treatment, helping medical professionals see and diagnose better—enhancing both physician dexterity and patient outcomes. Revenue for Olympus is predominantly driven by its Medical Business sector, which constitutes a significant portion of its overall profits, underscoring its transformation from a diversified manufacturer to a specialized player in healthcare technology. They are deeply committed to R&D, funneling substantial resources to innovate and bolster their portfolio in medical devices, particularly in fields like therapeutic interventions. While imaging products for consumers have historically been a notable segment, the shift toward medical technology aligns with broader market demands and ensures sustainable growth. This focus demonstrates Olympus's intent to maximize its competitive advantages, allowing it to remain at the forefront of its niche industries and effectively respond to global healthcare challenges.

Intrinsic Value
2 273.4 JPY
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Olympus Corp's Other Equity?
Other Equity
152.8B JPY

Based on the financial report for Sep 30, 2025, Olympus Corp's Other Equity amounts to 152.8B JPY.

What is Olympus Corp's Other Equity growth rate?
Other Equity CAGR 10Y
25%

Over the last year, the Other Equity growth was 25%. The average annual Other Equity growth rates for Olympus Corp have been 9% over the past three years , and 25% over the past ten years .

Back to Top